Phase 1 Trial of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 19 Jul 2013
At a glance
- Drugs Bendamustine (Primary) ; Dasatinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 20 May 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 24 Apr 2009 Planned number of patients changed from 48 to 60 as reported by ClinicalTrials.gov.
- 24 Apr 2009 Additional locations identified as reported by ClinicalTrials.gov.